Stay updated with breaking news from ஜீன் பிலிப் கோலட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The blood thinner apixaban was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from a new trial called ATLANTIS presented at the American College of Cardiology s 70th Annual Scientific Session. ....
Pfizer, Inc. (NYSE:PFE), Bristol-Myers Squibb Company (NYSE:BMY) - Pfizer-Bristol Myers' Eliquis Flops In Post-Heart Surgery Trial benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
ATLANTIS: Apixaban Not Superior to Standard Care After TAVR May 15, 2021 A Apixaban was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from the ATLANTIS trial presented May 15 at ACC.21 during a Late-Breaking Clinical Trial session. Researchers enrolled 1,510 patients at 50 centers in four countries (Spain, Italy, France and Germany) who underwent a successful TAVR procedure between 2016 and 2019. About one-third of the patients required anticoagulation therapy for reasons other than the TAVR procedure, mainly for atrial fibrillation (AFib). Half of this group and half of the remaining patients were randomly assigned to receive apixaban (5 mg bid). The remaining patients received standard care, which consisted of the vitamin K antagonist warfarin in patients requiring anticoagulation and an antiplatelet medication alone (typically aspirin) in those not requiring anticoagulation ....
email article A direct oral anticoagulant (DOAC) was no better than existing antithrombotic treatments after transcatheter aortic valve replacement (TAVR), according to ATLANTIS trial investigators. TAVR patients randomized to apixaban (Eliquis) instead of antiplatelet therapy or warfarin saw no reduction in the trial s primary endpoint, a composite of death, MI, stroke, systemic emboli, intracardiac or bioprosthesis thrombus, episode of deep vein thrombosis (DVT) or pulmonary embolism (PE), and major bleeding over 1-year follow-up (18.4% vs 20.1%, HR 0.92, 95% CI 0.73-1.16). These findings were consistent whether patients had an indication for oral anticoagulation or not, reported Jean-Philippe Collet, MD, PhD, of Pitié-Salpêtrière Hospital in Paris, at the American College of Cardiology (ACC) virtual meeting. ....